A company claims their supplement mix outlives rapamycin in mice — here’s why that needs scrutiny
A new study funded by longevity company Seragon reports that their combination treatment extends the lives of old mice more than rapamycin — currently the gold standard for lifespan extension in mice…
Rapamycin occupies a special place in aging research. Originally developed as an immunosuppressant for organ transplant patients, it has consistently extended lifespan in mice across multiple independent studies — even when given late in life. That consistency makes it a tough benchmark. So when a company claims their product surpasses it, the claim demands serious scrutiny.
The study, reviewed by Fight Aging!, treated aged mice — animals already well into old age when the intervention began. The combination includes several well-known supplements, but Seragon has not disclosed the full composition. That opacity is an immediate problem. Scientific claims can only be meaningfully evaluated when other researchers can reproduce them, which requires knowing exactly what was administered and at what doses.
A field with a pattern of overselling
The history of longevity research is littered with promising mouse results that failed to replicate. Supplement combinations are particularly difficult to evaluate: outcomes can vary dramatically across studies based on mouse strain, diet, housing conditions, and dozens of other variables. There’s also a pervasive publication bias — positive results get published, negative ones tend to disappear. None of that makes the Seragon results wrong, but it means they sit in a crowded category of preliminary findings that require independent confirmation before they carry real scientific weight.
The funding structure compounds this. Seragon financed research into their own product. Industry-sponsored studies aren’t automatically invalid, but they carry an added layer of uncertainty and require a higher bar for independent validation than neutrally funded work.
What would actually be convincing?
Researchers in the field broadly agree that convincing evidence for a new lifespan-extending intervention requires at minimum three things: replication in multiple independent laboratories, full transparency about composition and dosing, and ideally validation through the NIA Interventions Testing Program — a US government program that rigorously tests promising compounds in three genetically distinct mouse strains simultaneously. That program has a notable track record of humbling hyped interventions.
None of that work has been done here yet. The Seragon results may eventually prove to be the beginning of something real. But in a field where premature enthusiasm has caused repeated disappointment, an unreplicated, partially undisclosed study from an interested funder deserves a careful reception — however tempting the numbers look.